Literature DB >> 1469626

Cerebrospinal fluid transport and disposition of the quinolones ciprofloxacin and pefloxacin in rats.

U Jaehde1, M W Langemeijer, A G de Boer, D D Breimer.   

Abstract

The disposition of ciprofloxacin and pefloxacin in the rat cerebrospinal fluid (CSF) was investigated after i.v. and i.c.v. administration. After injection into the lateral ventricle, the terminal half-life of pefloxacin was shorter than that of ciprofloxacin. After i.v. infusions, the relative CSF exposure, expressed as CSF: area under the plasma concentration time curve ratio, were found to be 10.4 +/- 2.8% for ciprofloxacin and 42.4 +/- 3.0% for pefloxacin. The unit impulse response methodology was applied in order to assess the CSF transport profile. The plasma-CSF transport clearance of pefloxacin and the total amount of drug transported into the CSF were significantly higher compared with ciprofloxacin. Although pefloxacin exhibited a linear CSF transport profile, the plasma-CSF transport clearance of ciprofloxacin was found to be nonlinear at the dose level studied. Pefloxacin was converted in the brain to the active metabolite norfloxacin (N-desmethyl pefloxacin). The difference in CSF exposure of both quinolones and the presence of active metabolites of N-methylated quinolones in the CSF may be of clinical relevance in the treatment of CNS infections, but differences in antimicrobial activity have to be taken into account as well.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469626

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats.

Authors:  A Delon; L M Levasseur; M Giraudon; S Bouquet; W Couet
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

2.  Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats.

Authors:  L M Levasseur; A Delon; W R Greco; P Faury; S Bouquet; W Couet
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

3.  Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

4.  Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.

Authors:  Kazumasa Naruhashi; Ikumi Tamai; Natsuko Inoue; Hiromi Muraoka; Yoshimichi Sai; Nagao Suzuki; Akira Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

5.  Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats.

Authors:  S Marchand; C Pariat; S Bouquet; P Courtois; W Couet
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

6.  Pharmacokinetic-pharmacodynamic contributions to the convulsant activity of fluoroquinolones in rats.

Authors:  A Delon; S Bouquet; F Huguet; V Brunet; P Courtois; W Couet
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability.

Authors:  E Kłosińska-Szmurło; F A Pluciński; M Grudzień; K Betlejewska-Kielak; J Biernacka; A P Mazurek
Journal:  J Biol Phys       Date:  2014-07-18       Impact factor: 1.365

8.  Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin.

Authors:  R Nau; M Kinzig; T Dreyhaupt; H Kolenda; F Sörgel; H W Prange
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

9.  A new approach for early assessment of the epileptogenic potential of quinolones.

Authors:  A Delon; C Pariat; P Courtois; S Bouquet; W Couet
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.